232 related articles for article (PubMed ID: 23607800)
1. Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy.
Zhou Q; Gil-Krzewska A; Peruzzi G; Borrego F
Clin Exp Immunol; 2013 Jul; 173(1):131-9. PubMed ID: 23607800
[TBL] [Abstract][Full Text] [Related]
2. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
3. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.
Wang SY; Racila E; Taylor RP; Weiner GJ
Blood; 2008 Feb; 111(3):1456-63. PubMed ID: 18024795
[TBL] [Abstract][Full Text] [Related]
4. Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells.
Peruzzi G; Femnou L; Gil-Krzewska A; Borrego F; Weck J; Krzewski K; Coligan JE
J Immunol; 2013 Aug; 191(4):1883-94. PubMed ID: 23851692
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU
J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188
[TBL] [Abstract][Full Text] [Related]
6. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.
Veeramani S; Wang SY; Dahle C; Blackwell S; Jacobus L; Knutson T; Button A; Link BK; Weiner GJ
Blood; 2011 Sep; 118(12):3347-9. PubMed ID: 21768303
[TBL] [Abstract][Full Text] [Related]
7. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.
Terszowski G; Klein C; Stern M
J Immunol; 2014 Jun; 192(12):5618-24. PubMed ID: 24795454
[TBL] [Abstract][Full Text] [Related]
8. GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present.
Kern DJ; James BR; Blackwell S; Gassner C; Klein C; Weiner GJ
Leuk Lymphoma; 2013 Nov; 54(11):2500-5. PubMed ID: 23452151
[TBL] [Abstract][Full Text] [Related]
9. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.
Srivastava S; Pelloso D; Feng H; Voiles L; Lewis D; Haskova Z; Whitacre M; Trulli S; Chen YJ; Toso J; Jonak ZL; Chang HC; Robertson MJ
Cancer Immunol Immunother; 2013 Jun; 62(6):1073-82. PubMed ID: 23604103
[TBL] [Abstract][Full Text] [Related]
10. Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation.
Tang CC; Isitman G; Bruneau J; Tremblay C; Bernard NF; Kent SJ; Parsons MS
Clin Exp Immunol; 2015 Aug; 181(2):275-85. PubMed ID: 25644502
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
[TBL] [Abstract][Full Text] [Related]
12. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
[TBL] [Abstract][Full Text] [Related]
13. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy.
Clémenceau B; Gallot G; Vivien R; Gaschet J; Campone M; Vié H
J Immunother; 2006; 29(1):53-60. PubMed ID: 16365600
[TBL] [Abstract][Full Text] [Related]
14. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
[TBL] [Abstract][Full Text] [Related]
15. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
[TBL] [Abstract][Full Text] [Related]
16. Compromised NK cell-mediated antibody-dependent cellular cytotoxicity in chronic SIV/SHIV infection.
He X; Li D; Luo Z; Liang H; Peng H; Zhao Y; Wang N; Liu D; Qin C; Wei Q; Yan H; Shao Y
PLoS One; 2013; 8(2):e56309. PubMed ID: 23424655
[TBL] [Abstract][Full Text] [Related]
17. At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity.
Danielou-Lazareth A; Henry G; Geromin D; Khaznadar Z; Briere J; Tamouza R; Cayuela JM; Thieblemont C; Toubert A; Dulphy N
Eur J Immunol; 2013 May; 43(5):1383-8. PubMed ID: 23400905
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Cooley S; Burns LJ; Repka T; Miller JS
Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
[TBL] [Abstract][Full Text] [Related]
19. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells.
Capuano C; Romanelli M; Pighi C; Cimino G; Rago A; Molfetta R; Paolini R; Santoni A; Galandrini R
Cancer Res; 2015 Oct; 75(19):4097-108. PubMed ID: 26229120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]